These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 14603034)

  • 1. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
    Kennedy G; Komano J; Sugden B
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
    Komano J; Sugiura M; Takada K
    J Virol; 1998 Nov; 72(11):9150-6. PubMed ID: 9765461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LCR of EBV makes Burkitt's lymphoma endemic.
    Niller HH; Salamon D; Banati F; Schwarzmann F; Wolf H; Minarovits J
    Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
    Perez-Chacon G; de Los Rios C; Zapata JM
    Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.
    Hong M; Murai Y; Kutsuna T; Takahashi H; Nomoto K; Cheng CM; Ishizawa S; Zhao QL; Ogawa R; Harmon BV; Tsuneyama K; Takano Y
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):1-8. PubMed ID: 16180023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burkitt's lymphoma cells are resistant to programmed cell death in the presence of the Epstein-Barr virus latent antigen EBNA-4.
    Silins SL; Sculley TB
    Int J Cancer; 1995 Jan; 60(1):65-72. PubMed ID: 7814154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Epstein-Barr virus (EBV) nuclear antigen 1 subtypes in EBV-associated lymphomas from Brazil and the United Kingdom.
    MacKenzie J; Gray D; Pinto-Paes R; Barrezueta LFM; Armstrong AA; Alexander FA; McGeoch DJ; Jarrett RF
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2741-2745. PubMed ID: 10573169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
    Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
    J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus genetic variation in lymphoblastoid cell lines derived from Kenyan pediatric population.
    Simbiri KO; Smith NA; Otieno R; Wohlford EE; Daud II; Odada SP; Middleton F; Rochford R
    PLoS One; 2015; 10(5):e0125420. PubMed ID: 25933165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines.
    Touitou R; Arbach H; Cochet C; Feuillard J; Martin A; Raphaël M; Joab I
    J Gen Virol; 2003 Apr; 84(Pt 4):949-957. PubMed ID: 12655096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus.
    Rooney C; Howe JG; Speck SH; Miller G
    J Virol; 1989 Apr; 63(4):1531-9. PubMed ID: 2538644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.
    Majerciak V; Yang W; Zheng J; Zhu J; Zheng ZM
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication.
    Van Scoy S; Watakabe I; Krainer AR; Hearing J
    Virology; 2000 Sep; 275(1):145-57. PubMed ID: 11017796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease.
    Hammerschmidt W; Sugden B
    Trends Mol Med; 2004 Jul; 10(7):331-6. PubMed ID: 15242681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of viral gene expression and genome persistence in CD23-positive and -negative subpopulations of Epstein-Barr-virus-infected BL2 cells.
    Doyle MG; Crawford DH
    Intervirology; 1994; 37(5):236-44. PubMed ID: 7698878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1.
    Watanabe A; Maruo S; Ito T; Ito M; Katsumura KR; Takada K
    J Virol; 2010 Mar; 84(6):2893-901. PubMed ID: 20042495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells.
    Leao M; Anderton E; Wade M; Meekings K; Allday MJ
    J Virol; 2007 Jan; 81(1):248-60. PubMed ID: 17035311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
    Hochberg D; Middeldorp JM; Catalina M; Sullivan JL; Luzuriaga K; Thorley-Lawson DA
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):239-44. PubMed ID: 14688409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus maintains lymphomas via its miRNAs.
    Vereide DT; Seto E; Chiu YF; Hayes M; Tagawa T; Grundhoff A; Hammerschmidt W; Sugden B
    Oncogene; 2014 Mar; 33(10):1258-64. PubMed ID: 23503461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.